bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
CMVAB

Order Name:
CMV IgG 

 
Useful For:
Determination of IgG antibodies to Cytomegalovirus in human serum.
 
Methodology:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName:
Cytomegalovirus Antibody IgG
Cytomegalovirus  IgG
 
 
 
Test Code:
CMVAB

Order Name:
CMV IgG 

 
Collection Specimen Or Container:
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 2 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: 4+ reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum (keep in original tube) Refrigerated, 2oC to 8oC 8 hours
Serum Refrigerated, 2oC to 8oC 14 days
Frozen, -20oC 1 month
 
 
 
Test Code:
CMVAB

Order Name:
CMV IgG 

 
Method detail:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
Schedule:
Tested daily (24 hours)
 
 
Turnaround Time:
Specimen collected to reported within 2:00 hours (120 mins)
 
Performing Location:
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
CMVAB

Order Name:
CMV IgG 

 
 
Clinical Information:
Infections with Cytomegalovirus (CMV), a member of the herpesvirus family, are common in man and are usually mild and asymptomatic. However, in pregnant women, newborns, and immunocompromised individuals CMV infections may pose a significant medical risk.

The provision of seronegative blood products to selected patients remains a vital consideration in patient management. Serologic tests can be used to identify seronegative individuals5 and seronegative donors of organs or blood products. In utero infection may result in sequelae of varying degree including mental retardation, chorioretinitis, hearing loss and neurologic problems. Since the risk of in utero virus transmission
and CMV related damage of the fetus is strongly increased during primary infection, reliable recognition of primary CMV infections is of high importance for pregnant women. Thus, the presence of CMV-specific IgG antibody does not assure protection from disease. An individual may undergo primary infection with CMV, reinfection with exogenous virus or reactivation of latent virus.

If primary infection needs to be excluded, CMV IgG reactive samples should be tested for CMV IgM and CMV IgG Avidity. A positive CMV IgM result in connection with low avidity result is a strong indicator of a primary CMV infection within the last 4 months.  A substantial rise in anti-CMV IgG concentrations in sequential
samples taken from an individual accompanied by the presence of anti-CMV IgM could also indicate serological evidence of active infection.
 
Reference Value:
Non reactive
 
Clinical Reference:
Manufacturer’s Reagent package insert, Architect CMV IgM, March 2015, Abbott Ireland Diagnostics Division, Finisklin Business Park, Sligo, Ireland.